Compare

PTC Therapeutics/$PTCT

1D1W1M3M6MYTD1Y5YMAX

About PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Ticker
$PTCT
Sector
Health
Primary listing
NASDAQ
Employees
991

PTC Therapeutics Metrics

BasicAdvanced
$5.1B
-
-$1.28
0.49
-

What the Analysts think about PTC Therapeutics

Analyst ratings (Buy, Hold, Sell) for PTC Therapeutics stock.
Analyst projections of the future price of PTC Therapeutics stock.

Bulls say / Bears say

Sephience is scaling quickly: third-quarter sales reached $182 million, up 20% from the prior quarter, and PTC raised its 2026 product revenue outlook to $960–990 million. Management also expects cash flow breakeven this year. (PTC Therapeutics)
Votoplam’s 24-month extension results showed dose-dependent slowing of disease progression, including 52% at the higher dose in Stage 2 patients versus an external natural-history cohort. Novartis has begun a global Phase 3 trial, which also triggered a $50 million milestone payment to PTC. (PTC Therapeutics, PTC Therapeutics)
ST-920 adds a potential Fabry disease launch to the pipeline: the Phase 1/2 study showed a positive average eGFR slope at 52 weeks, and PTC expects to complete its FDA application in Q4 2026, with a possible launch in 2027. (PTC Therapeutics)
PTC’s older Duchenne franchise is under pressure: Translarna lost its EU authorisation and PTC withdrew its US application after FDA feedback, while Emflaza sales fell to $25.1 million from $35.2 million as generics gained ground. (SEC)
Vatiquinone faces a significant regulatory hurdle: the FDA said the evidence did not establish efficacy and asked for another adequate, controlled study. PTC’s new study uses an open-label treatment arm with a matched natural-history comparison, so approval remains uncertain. (SEC)
Strong sales have not yet produced steady earnings: PTC reported a $51.7 million third-quarter net loss and $45.9 million in net interest expense, with $536 million of debt and a $2.3 billion liability linked to sold future royalties. These financing costs may limit the benefit of revenue growth to shareholders. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.

PTC Therapeutics Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

PTC Therapeutics Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing PTC Therapeutics

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.